Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of E2609 in Healthy Subjects

A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of E2609 in Healthy Subjects

The purpose of this single-center, randomized, double-blind, placebo-controlled, study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of E2609 when administered to healthy elderly subjects.

Key Inclusion Criteria:

• Healthy males and females
• Female subjects must be of non-childbearing potential
• Aged 50 to 85 years, inclusive BMI of 18 to 32 kg/m2 at screening
• Thyroid function tests within normal rangeMini-Mental State Examination score of 28-30, inclusive

Key Exclusion Criteria:

• History of neurological abnormalities, including seizures
• Any clinically significant abnormality of the ECG at Screening and Baseline including QTc prolongation
• History of ischemic heart disease, cardiac arrhythmias, cerebrovascular diseases
• Other medical conditions that are not stably controlled
• Presence of orthostatic hypotension